Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Nuformix Plc | LSE:NFX | London | Ordinary Share | GB00BYW79Y38 | ORD 0.05P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.05 | 0.00 | 08:00:05 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.045 | 0.06 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | -859k | -0.0010 | -0.50 | 409.65k |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 0.05 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 05/11/2024 | 14:25 | UK RNS | Nuformix PLC Director/PDMR Dealings |
| 04/11/2024 | 10:17 | UK RNS | Nuformix PLC Result of General Meeting |
| 16/10/2024 | 12:37 | UK RNS | Nuformix PLC Publication of Prospectus & Notice of GM |
| 20/9/2024 | 13:24 | UK RNS | Nuformix PLC £300,000 Fundraise |
| 18/6/2024 | 17:37 | ALNC |  IN BRIEF: Nuformix shares fall despite interim loss narrowing |
| 18/6/2024 | 06:00 | UK RNS | Nuformix PLC Half-year Report |
| 17/6/2024 | 09:37 | ALNC | Nuformix touts patent wins for idiopathic pulmonary fibrosis treatment |
| 17/6/2024 | 06:00 | UK RNS | Nuformix PLC Patent Update |
| 19/3/2024 | 14:39 | UK RNS | Nuformix PLC Result of AGM |
| 01/3/2024 | 10:31 | ALNC | IN BRIEF: Nuformix announces subscription to raise GBP150,000 |
Nuformix (NFX) Share Charts1 Year Nuformix Chart |
|
1 Month Nuformix Chart |
Intraday Nuformix Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 31/10/2024 | 18:10 | NUFORMIX September 2 Presentations - Massive Upside NFX | 551 |
| 18/5/2023 | 06:08 | Nuformix plc | 9,116 |
| 28/1/2021 | 15:43 | ****NFX2021**** | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-11-20 16:01:32 | 0.05 | 49,769 | 23.89 | O |
| 2024-11-20 16:01:31 | 0.05 | 12,442 | 5.97 | O |
| 2024-11-20 15:01:13 | 0.05 | 49,770 | 23.89 | AT |
| 2024-11-20 15:01:13 | 0.05 | 12,442 | 5.97 | AT |
| 2024-11-20 14:45:37 | 0.05 | 1,044,899 | 506.78 | O |
| Top Posts |
|---|
Posted at 21/11/2024 08:20 by Nuformix Daily Update Nuformix Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker NFX. The last closing price for Nuformix was 0.05p.Nuformix currently has 819,309,368 shares in issue. The market capitalisation of Nuformix is £409,655. Nuformix has a price to earnings ratio (PE ratio) of -0.50. This morning NFX shares opened at - |
Posted at 29/10/2024 17:34 by for fx sake There are 819m shares in issue right now worth about 0.055p per share. There will shortly be around 1.4bn in issue.1.4bn shares at 2p values this company at 28m. We are currently worth 0.5m.Who is going to £28m in 6 months to buy a company they could buy for less than 1m now? |
Posted at 25/9/2024 13:04 by socionomics Do the opposite of what Sheedy does and you won't go far wrong. BT/VOD/ITV/OPTI/SBTXHe has only ever been bullish on NFX (at 6p. WTF! The guy is clueless. The laughing stock of ADVFN. |
Posted at 05/9/2024 13:16 by jotoha2 The idle chatter was just before the last fund raise , so no substance behind it , question is has Dan something to sell , he needs a White Knight with lots of cash! A low price takeout and a couple of years with a decent salary will probably be the best for him , it looks like the end quite soon. |
Posted at 08/8/2024 11:54 by leadersoffice A lot of f e c k I n g about with the share price. Are er ever going to get back to 1p and over ?? |
Posted at 06/8/2024 11:11 by socionomics This is NFX. Have you been drinking? |
Posted at 06/8/2024 11:05 by citys2874 CGH may do 400 percent today worth buying today. This and NFX having a great morning |
Posted at 31/7/2024 10:44 by washingmachine If he pulls it offNFX will 10 bag minimum Excellent risk / reward here |
Posted at 15/7/2024 17:55 by nobbygnome Skull driller is one of his many avatars. He claims to be a guru but his record of shorts and longs is truly shocking….SYME and NFX are just two of his disasters! |
Posted at 18/6/2024 15:43 by for fx sake You might need to recalculate that. 10m divided by 819.31m shares is not 12p per share |
Posted at 14/12/2021 17:53 by sentiment riles Lanstead Investment – Q&AQ. Why did Nuformix choose the Sharing Agreements with Lanstead? A: The sharing agreements with Lanstead allows Nuformix to benefit from positive share price performance over 20 months and the funding supports Nuformix’s activities over that period. We see a number of positive catalysts for Nuformix over the coming months, in particular as we make NXP004 Phase 1 ready and continue to strengthen the IP around NXP004, which should be positive for the share price as these are announced. Q: Is Lanstead entitled to invest monthly at a fixed discount to the prevailing Nuformix share price from month-to-month? A: No. Lanstead will be issued and will immediately pay for the shares it subscribes for at 1.5p per share. The number of shares issued to Lanstead is fixed and does not change. However, the amount from Lanstead due to the Company under the sharing agreements is adjustable upwards or downwards at each of the 20 monthly settlements that follow. For example; the approximate amount in any particular month will be 10% more than £82,500 if the share price is 10% higher than the 2.0p benchmark price (“BMP”) or 10% less than £82,500 if the share price is 10% lower than the BMP. Q: Can Lanstead benefit by the share price being lower than the 2.0p BMP, rather than going higher than 2.0p? A: No. Lanstead makes more money the higher the share price is. Through the sharing agreements Lanstead shares some, but not all, of the upside when the share price appreciates with Nuformix. The sharing agreements are an incentive for Nuformix to perform, thereby benefitting all shareholders including Lanstead. If the share price over 20 months averages double the BMP (i.e. 4.0p) then the Company will receive double the initial Lanstead subscription of £1.65 million (i.e. £3.30 million instead of £1.65 million). If the share price over 20 months averages half the BMP (i.e. 1.0p) then the Company will ultimately receive half the initial Lanstead subscription (i.e. £0.825 million instead of £1.65 million). The projected outcome for Nuformix is contractually clear and the value of Lanstead’s investment is greater if the company’s share price is higher. It is important to note that Lanstead participates in the majority, but not all of the upside in any future Nuformix share price appreciation. The bottom line is that Lanstead makes more money as the share price rises and does not derive any advantage from a decline in the share price. Q: Can Lanstead trade its Nuformix shares? A: Lanstead has a demonstrable track record of being a longer-term supportive shareholder to its investee companies. Like any institutional investor Lanstead only invests in companies where it can see strong potential for share price appreciation. Lanstead is free to buy and sell shares just like any other shareholder and it is required to disclose movements of >1% as a significant disclosable shareholder. Unlike other shareholders, Lanstead has an uncapped commitment through the sharing agreements to remit amounts each month to Nuformix based on the prevailing share price. Therefore whilst Lanstead may take a profit along the way (like any shareholder) and cover its downside risk on the investment (just like any shareholder), Lanstead also has an incentive (unlike other shareholders) to maintain a significant on-going shareholding because of its uncapped exposure on the amounts due to Nuformix over the 20 months of the sharing agreements should the Nuformix shares appreciate |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
